A discounted cash flow analysis suggests Savaria Corporation's stock may be trading significantly below its intrinsic value, presenting a potential opportunity for investors. However, experts caution that valuation models are only one piece of the investment puzzle.
Focused Wealth Management significantly reduced its stake in a short-term Treasury ETF, signaling a strategic pivot towards equities as stock markets reach new highs. The move highlights a broader trend of capital rotation in response to shifting risk appetites.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
One of Ethereum's largest holders faces a potential multi-billion dollar liquidation as prices slide, prompting urgent deleveraging moves that could ripple across crypto markets.
Backed by a major U.S. government loan and a surge in private equity, USA Rare Earth is accelerating its domestic mining and manufacturing projects, positioning itself at the forefront of a critical national strategy.
Biotech firm Definium Therapeutics appoints seasoned commercial executive Roger Adsett to its board, signaling a strategic shift towards commercialization as key late-stage trial data approaches.
Eli Lilly announces a massive new manufacturing facility in Pennsylvania, part of a strategic pivot by major drugmakers to onshore production amid trade tensions and soaring demand for weight-loss drugs.
While market volatility rattles investors, Volvere plc (LON:VLE) has quietly engineered a remarkable three-year run, with its share price soaring 148%. We examine the fundamentals behind the surge and ask if the momentum can hold.
Microsoft's second-quarter earnings smashed expectations, fueled by a 26% surge in cloud revenue that crossed the $50 billion mark for the first time. The tech giant's aggressive AI investments are now driving significant growth across its enterprise stack.
Shares of electric air taxi developer Joby Aviation tumbled sharply Thursday as the market reacted to the company's announcement of a major new fundraising effort, raising concerns over potential shareholder dilution.
Despite reporting a near-doubling of annual net income and raising its 2026 outlook, electronics manufacturer Celestica saw its shares drop sharply Thursday as the market judged its stellar results to be already reflected in the price.
The trial of Marius Borg Høiby, son of Crown Princess Mette-Marit, opens in Oslo, exposing a profound crisis for the Norwegian monarchy as he faces charges including rape and assault.
A draft proposal from disaster response firm Gothams LLC, obtained by The Guardian, outlined terms for a trucking and logistics monopoly in Gaza that would guarantee extraordinary returns, raising questions about oversight and ethics in post-conflict rebuilding.
A Foxboro woman's two-year struggle with a defective high-end oven underscores the enduring power of state consumer protection laws, even after a manufacturer's warranty expires.
Meta Platforms' relentless investment in artificial intelligence infrastructure is set to drive capital expenditures to unprecedented levels in 2026, raising questions about long-term returns for the cash-rich tech giant.
Alibaba Group is making a massive, multi-billion yuan bet to integrate its Qwen AI assistant across its ecosystem and develop its own AI chips, signaling a strategic pivot to reduce foreign dependency and deepen user engagement amid intense competition.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
Despite posting blockbuster profits, Microsoft shares plunged 10% after its latest earnings, erasing hundreds of billions in market value. We examine whether Wall Street's reaction to cloud growth and AI spending fears is an overreaction or a prudent pause.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
